Royalty Pharma acquires royalty interest in AstraZeneca’s cliramitug for up to $425 million from Neurimmune
NEW YORK, July 22, 2026 (GLOBE NEWSWIRE) — Royalty Pharma plc (Nasdaq: RPRX) today announced that it has…
AstraZeneca’s Datroway and Enhertu candidates receive EU approval
Drugmaker AstraZeneca said on Monday that its breast cancer therapy Datroway has been recommended for approval in the…
AIM ImmunoTech Reports Positive Mid-Year Interim Clinical Progress from Phase 2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer
Company remains on track for a planned December 2026 evaluation of the clinical trial’s primary endpoint OCALA, Fla.,…
US FDA pushes back decision on Astrazeneca’s camizestrant
Drugmaker Astrazeneca said the US Food and Drug Administration had pushed back its decision on camizestrant after requesting…
Astrazeneca’s Imfinzi receives green light from US FDA
Drugmaker Astrazeneca said on Friday that Imfinzi has been approved in the US as part of the first…